Infliximab is a chimeric monoclonal antibody against tumour-necrosis factor-α (TNF-α), which has demonstrated efficacy in patients who do not respond to traditional therapies 2,4. Since then ...

The Company announced last year through a partnership with Intract Pharma, an exclusive license to INT-023 (now TH023), an oral anti-TNF-α monoclonal antibody. Tharimmune licensed global ...

(In justifying to Centocor why it would be wise to invest in the development of antibodies to lymphotoxin and TNF, I mentioned the possibility of their therapeutic usefulness in autoimmune diseases.) ...

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha Tharimmune Inc. Mon, Mar 24, 2025, 8:00 AM 7 min read ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation ...